2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better

In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.

 
More Headlines

Follow worldbiztoday on Twitter

US Stocks